Drug Profile


Alternative Names: IPX-203

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Impax Pharmaceuticals
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Phase II Parkinson's disease

Most Recent Events

  • 01 Nov 2016 Impax initiates enrolment in a phase II trial in Parkinson's disease (In adults, In elderly) in USA (NCT03007888)
  • 09 Aug 2016 Efficacy and adverse events data from a phase IIa trial in Parkinson's disease released in Impax Second Quarter Report 2016
  • 01 Aug 2016 Impax completes a phase IIa trial in Parkinson's disease (In adults, In elderly) in USA (NCT02271503)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top